US FDA has withdrawn the approval of the NDA for Wellcovorin, at the request of GSK (GSK LN)

The withdrawal of the NDA approval for Wellcovorin at the request of GSK suggests strategic recalibration from the company regarding its product pipeline.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

NATO Spokesperson says it is clear the US expects concrete commitments and action to ensure freedom of navigation in the Strait of Hormuz

German Chancellor Merz says the situation in the Middle East requires a response from Germany, also with regards to energy

US FDA has withdrawn the approval of the NDA for Wellcovorin, at the request of GSK (GSK LN)

Starbucks' (SBUX) CEO has recruited Chipotle executive Piacentini as the Co.'s new coffeehouse design and development officer

Yemen’s Houthi leader says operations follow a planned strategy that accounts for the conflict’s potential duration; operation will escalate, with possible surprise actions aligned with developments on the ground

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This may raise concerns about GSK's near-term prospects and could influence investor sentiment negatively, with potential ramifications for the stock and the broader pharmaceuticals sector. Keep an eye on how this affects GSK's market position and collaboration opportunities moving forward.

Related headlines

The whole workspace, free to try.

Try it free